Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

Authors von Websky K, Reichetzeder C, Hocher B

Published Date November 2013 Volume 2013:9 Pages 681—694

DOI http://dx.doi.org/10.2147/VHRM.S40035

Received 8 August 2013, Accepted 24 September 2013, Published 1 November 2013

Karoline von Websky, Christoph Reichetzeder, Berthold Hocher

Institute of Nutritional Science, University of Potsdam, Potsdam-Rehbrücke, Germany

Abstract: Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently approved oral dipeptidyl peptidase-4 inhibitor, has a unique pharmacological profile. The convenient, once-daily dosing does not need adjustment in patients with hepatic and/or renal impairment. In clinical studies linagliptin shows an important reduction of blood glucose with an overall safety profile similar to that of placebo. So far, the combination of linagliptin and insulin has been tested in three major clinical studies in different populations. It has been shown that linagliptin is an effective and safe add-on therapy to insulin in patients with T2DM. The efficacy and safety of this combination was also shown in vulnerable, elderly T2DM patients and in patients with T2DM and renal impairment. Favorable effects regarding the counteraction of hypoglycemia make linagliptin especially interesting as an add-on therapy to insulin. This review aims to present the existing clinical studies on the efficacy and safety of linagliptin as add-on therapy to insulin in patients with T2DM in the context of current literature. Additionally, the possible advantages of linagliptin as an add-on therapy to insulin in relation to cardiovascular safety, patient-centered therapy and the prevention of hypoglycemia, are discussed.

Keywords: incretin, dipeptidyl peptidase-4, glucagon like peptide-1, glycemic control, renal impairment, hypoglycemia

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Optimal management of infrainguinal arterial occlusive disease

Pennywell DJ, Tan TW, Zhang WW

Vascular Health and Risk Management 2014, 10:599-608

Published Date: 24 October 2014

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K

Vascular Health and Risk Management 2013, 9:719-727

Published Date: 15 November 2013

Lipid profiles and inflammatory markers after periodontal treatment in children with congenital heart disease and at risk for atherosclerosis

Bresolin AC, Pronsatti MM, Pasqualotto LN, Nassar PO, Jorge AS, Silva EA, Nassar CA

Vascular Health and Risk Management 2013, 9:703-709

Published Date: 11 November 2013

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W

Vascular Health and Risk Management 2013, 9:21-28

Published Date: 23 January 2013

Corrigendum

Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2013, 9:1-2

Published Date: 27 December 2012

Optimizing visualization in enhanced depth imaging OCT in healthy subjects and patients with retinal pigment epithelial detachment

Reznicek L, Vounotrypidis E, Seidensticker F, Kortuem K, Kampik A, Neubauer AS, Wolf A

Clinical Ophthalmology 2012, 6:1915-1920

Published Date: 21 November 2012